NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

幹細胞研究的全球市場

Stem Cells

出版商 Global Industry Analysts, Inc. 商品編碼 243086
出版日期 內容資訊 英文 162 Pages
商品交期: 最快1-2個工作天內
價格
幹細胞研究的全球市場 Stem Cells
出版日期: 2021年04月01日內容資訊: 英文 162 Pages
簡介

本報告,分析幹細胞研究的全球市場,提供美國/歐洲/其他地區的全面地區別分析,推估/預測2008-2017年的年度業績,同時彙整主要/利基參與者共87家的企業檔案資料,由下列摘要形式闡述。

第1章 簡介、方法論、產品定義

第2章 報告摘要

第3章 市場概要

  • 概要
  • 過去的主要成果
  • 幹細胞研究上的歷史大事件
  • 新成長領域
  • 整型外科用產品:具潛力的成長部門
  • 臍帶血幹細胞的實用功能
  • 課題
  • 幹細胞研究與倫理角度

第4章 市場的動態與趨勢

  • 北美支配全球的幹細胞市場
  • 幹細胞的躍進重新形成醫療領域
  • 韓國公開世界最初的體性幹細胞式治療
  • 對新技術的莫大關注
  • 倫理問題與發生期狀態:幹細胞的主要市場阻礙因素
  • 幹細胞治療上的醫療旅遊的上昇
  • 政府法規無法防止幹細胞治療的醫療旅遊
  • 幹細胞專利上美國與日本創造出與歐洲的巨大差距

第5章 幹細胞市場動態:種類別

  • 成體幹細胞所握有的莫大可能性
  • 成體幹細胞與胚胎幹細胞:比較
  • 低風險的投資
  • 成體幹細胞聚集較多的研究用投資
  • 低通用性:成體幹細胞的主要限制因素
  • 造血幹細胞:享受持續的成功
  • 阻礙因素
  • 間質幹細胞:具潛力的治療選項
  • 隔離性的難度與低理解度阻礙成長
  • 誘發型多功能幹細胞:ESC的替代
  • iPS發現的概要
  • 醫藥品開發:iPS的主要應用
  • 再生醫療
  • iPS細胞銀行的建立
  • 難治性/先天性疾病的治療
  • 內臟器官治療
  • 胚胎幹細胞改變了醫療領域
  • 安全性與有效性資料的不足持續為問題

第6章 用途別幹細胞研究

  • 疾病管理上的幹細胞
  • 再生醫療上的幹細胞治療
  • 幹細胞治療:對神經障礙具潛力的治療
  • 被要求大規模研究的心臟血管疾病上的早期成果建立
  • 癌症的幹細胞治療
  • 跨足個人醫療的幹細胞
  • 高齡化人口所促進的整型外科幹細胞市場
  • 其他疾病
  • 藥物傳遞上的幹細胞
  • 醫藥品開發用工具

第7章 法規環境

  • 支配幹細胞研究的法律:分裂的世界
  • 主要國家的幹細胞研究相關法律與規範

第8章 產品概要

  • 幹細胞研究
  • 幹細胞:解說
  • 幹細胞的種類
  • 胚胎幹細胞
  • 成體幹細胞
  • 其他主要細胞種類
  • 幹細胞:特性
  • 自然再生能力
  • 可能性
  • 多樣潜在力的定義
  • 幹細胞的辨識
  • 幹細胞:應用
  • 幹細胞的歷史
  • 幹細胞:服務與產品
  • 幹細胞產品/服務的重大性

第9章 研究的飛躍式發現

第10章 產品介紹/創新

第11章 近期業界活動

第12章 策略企業發展:歷史展望材料

第13章 關注全球的主要參與者

第14章 全球市場展望

  • 美國
  • 歐洲
  • 其他地區

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6142

Abstract:

Global Stem Cells Market to Reach $15.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Stem Cells estimated at US$9.1 Billion in the year 2020, is projected to reach a revised size of US$15.1 Billion by 2027, growing at aCAGR of 7.4% over the period 2020-2027. Adult Stem Cells, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$12.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Product Types segment is readjusted to a revised 8.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $2.7 Billion, While China is Forecast to Grow at 6.9% CAGR

The Stem Cells market in the U.S. is estimated at US$2.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2027 trailing a CAGR of 6.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6% CAGR.

Select Competitors (Total 66 Featured) -

  • apceth Biopharma GmbH
  • Athersys Inc.
  • AVIVA BioSciences Corporation
  • BioE Inc.
  • Bone Therapeutics SA
  • Cesca Therapeutics Inc.
  • Cryo-Cell International Inc.
  • Cytori Therapeutics Inc.
  • ESI BIO
  • Gamida Cell Ltd.
  • Holostem Terapie Avanzate
  • International Stem Cell Corp.
  • Kangstem Biotech. Ltd.
  • Lonza Group Ltd.
  • Mesoblast Ltd.
  • Neuralstem Inc.
  • Nuvasive Inc.
  • OncoMed Pharmaceuticals Inc.
  • Osiris Therapeutics Inc.
  • Promethera Biosciences S.A.N.V
  • Reliance Life Sciences
  • ReNeuron Group Plc.
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Stempeutics Research Pvt. Ltd.
  • Takara Bio USA Inc.
  • TiGenix NV
  • U.S Stem Cell Inc.
  • ViaCord

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Stem Cells - Offering Potential for Breakthrough Therapeutic Discoveries
    • Recent Market Activity
    • Select Approved Stem Cell Products
    • Stem Cells Bypass Use of Animal Models in Drug Discovery Programs
    • Trends Related to Stem Cell Clinical Trials
    • Select Stem Cell Pipeline Analysis
    • Current & Future Analysis
    • Stem Cell Research Funding Policies across the World
    • Japan and US - Pioneering Induced Pluripotent Stem Cell (iPSC) Research
    • Adult Stem Cells Deemed More Ethical, More Research Needed to Increase Clinical Applications
    • Dental Mesenchymal Stem Cells - Emergence of a Niche Market
    • For-Profit, Unregulated Clinics: The Flipside of Stem Cell Research
    • Unproven Therapies Do Online Rounds as Effective Treatment Options - A Cause of Concern
  • 2. FOCUS ON SELECT PLAYERS
    • Athersys, Inc. (USA)
    • Apceth GmbH & Co.KG (Germany)
    • AVIVA BioSciences Corporation (USA)
    • BioE, Inc. (USA)
    • Bone Therapeutics SA (Belgium)
    • Cesca Therapeutics, Inc. (USA)
    • Cryo-Cell International, Inc. (USA)
    • Cytori Therapeutics, Inc. (USA)
    • ESI BIO, a Division of BioTime Inc. (USA)
    • Gamida Cell Ltd. (Israel)
    • Holostem Terapie Avanzate (Italy)
    • International Stem Cell Corporation (USA)
    • Kangstem Biotech., Ltd. (Korea)
    • Lonza Group Ltd (Switzerland)
    • Mesoblast Ltd. (Australia)
    • Neuralstem, Inc. (USA)
    • Nuvasive, Inc. (USA)
    • Osiris Therapeutics, Inc. (USA)
    • OncoMed Pharmaceuticals, Inc (USA)
    • PROMETHERA Biosciences S.A.N.V (Belgium)
    • Reliance Life Sciences (India)
    • ReNeuron Group Plc. (UK)
    • STEMCELL Technologies, Inc. (Canada)
    • Stemedica Cell Technologies, Inc (USA)
    • Stempeutics Research Pvt. Ltd. (India)
    • Takara Bio USA Inc (USA)
    • TiGenix NV (Belgium)
    • U.S Stem Cell, Inc. (USA)
    • ViaCord, LLC (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Researchers at UCLA Successfully Develop 3D Lung Organoids using Stem Cells
    • Embryonic Stem Cell Gene Nanog Found to Reverse Aging
    • Canadian and Dutch Scientists Finds the "Genetic Switch" to Increase Stem Cell Volume from Cord Blood
    • The Boston Program Pioneers Cell-based Personalized Diabetes Treatment
    • iPSCs Provide Valuable Source for Retinal Transplants and Other Applications
    • Albumin-Free Culture of Pluripotent Stem Cells Enables Application in Cardiac Disorders
    • Stem Cell Therapy - An Alternative to Orthopedic Surgery in Younger Patients?
    • Application of Plant Stem Cells in Cosmetic Treatments - Myths Busted
    • Adverse Reactions of Stem Cell-Face Lift Therapy
    • Stem Cell-Breast Enhancement
    • Other Innovations Using Stem Cells
    • New Stem Cell Software & Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Adult Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Adult Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 11: USA Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 12: USA 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 13: USA Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • CANADA
    • TABLE 15: Canada Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 16: Canada 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 17: Canada Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Canada 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 21: Japan Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 22: Japan 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • CHINA
    • TABLE 23: China Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 24: China 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 25: China Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: China 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • EUROPE
    • TABLE 27: Europe Current & Future Analysis for Stem Cells by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 28: Europe 7-Year Perspective for Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 29: Europe Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Europe 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 31: Europe Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • FRANCE
    • TABLE 33: France Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 34: France 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 35: France Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 36: France 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • GERMANY
    • TABLE 37: Germany Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Germany 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 39: Germany Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Germany 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • ITALY
    • TABLE 41: Italy Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Italy 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 43: Italy Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Italy 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 45: UK Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 46: UK 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 47: UK Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 48: UK 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 49: Rest of Europe Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of Europe 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 51: Rest of Europe Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 52: Rest of Europe 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 53: Asia-Pacific Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 54: Asia-Pacific 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 55: Asia-Pacific Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Asia-Pacific 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 57: Rest of World Current & Future Analysis for Stem Cells by Product Type - Adult Stem Cells and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 58: Rest of World 7-Year Perspective for Stem Cells by Product Type - Percentage Breakdown of Value Sales for Adult Stem Cells and Other Product Types for the Years 2020 & 2027
    • TABLE 59: Rest of World Current & Future Analysis for Stem Cells by Application - Regenerative Medicine and Drug Discovery & Development - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 60: Rest of World 7-Year Perspective for Stem Cells by Application - Percentage Breakdown of Value Sales for Regenerative Medicine and Drug Discovery & Development for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 66